NDA 213801 · Apgdi
Myrbetriq Granules
Mirabegron · Oral · beta3-Adrenergic Agonist
Priority reviewLast checked: Nov 19, 2026Latest source record: Mar 25, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Mar 25, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
169
33 Phase 3, 19 recruiting
FAERS reports
39,172
19,045 serious, 3,335 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 1, 2024.
MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of: • Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either alone or in combination with the muscarinic antagonist solifenacin succinate. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) MYRBETRIQ Granules is a beta-3 adrenergic agonist indicated for the treatment of NDO in pediatric patients aged 3 years and older. ( 1.2 ) 1.1 Adult Overactive Bladder (OAB) MYRBETRIQ Monotherapy MYRBETRIQ ® is indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. MYRBETRIQ Combination Therapy with Solifenacin Succinate MYRBETRIQ, in combination with the muscarinic antagonist solifenacin succinate, is indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity (NDO) MYRBETRIQ Granules MYRBETRIQ ® Granules is indicated for the treatment of NDO in pediatric patients aged 3 years and older. MYRBETRIQ MYRBETRIQ is indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more.
Mechanism: Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in vitro laboratory experiments using the cloned human beta-3 AR. Mirabegron relaxes the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle by activation of beta-3 AR which increases bladder capacity. Although mirabegron showed very low intrinsic activity for cloned human beta-1 AR and beta-2 AR, results in humans indicate that beta-1 AR stimulation occurred at a mirabegron dose of 200 mg.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- MYRBETRIQ GRANULES · MIRABEGRON 8MG/ML · FOR SUSPENSION, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Mirabegron" as an intervention, any sponsor and status, largest first.
Astellas Pharma Europe B.V.Astellas (ALPMY)
NCT01972841 · 3,527 participants · Start Nov 5, 2013 · Primary completion Oct 22, 2015
Drug: Solifenacin succinate; Mirabegron and 2 more · For: Urinary Bladder Overactive; Urinary Bladder Diseases\Urologic Diseases; Overactive Bladder and 1 more
Sites: Mobile, Alabama; Chandler, Arizona; Phoenix, Arizona · 435 sites in all
- Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00688688 · 2,792 participants · Start Apr 25, 2008 · Primary completion May 6, 2010
Drug: Mirabegron; Tolterodine and 2 more · For: Urinary Bladder, Overactive
Sites: Homewood, Alabama; Huntsville, Alabama; Mobile, Alabama · 308 sites in all
- Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00689104 · 2,336 participants · Start Apr 28, 2008 · Primary completion Mar 24, 2009
Drug: Mirabegron; Tolterodine and 2 more · For: Urinary Bladder, Overactive
Sites: Auchenflower, Australia; Clayton, Australia; Kogarah, Australia · 218 sites in all
- A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)Pivotal-lookingCompleted
Astellas Pharma Europe Ltd.Astellas (ALPMY)
NCT01908829 · 2,174 participants · Start Jul 10, 2013 · Primary completion Nov 24, 2014
Drug: mirabegron 25 mg; mirabegron 50 mg and 6 more · For: Urinary Bladder Diseases; Urinary Bladder Overactive; Urologic Diseases
Sites: Tucson, Arizona; Buena Park, California; Los Angeles, California · 219 sites in all
- A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00662909 · 2,149 participants · Start Mar 28, 2008 · Primary completion Apr 22, 2009
Drug: Mirabegron; Placebo · For: Urinary Bladder, Overactive
Sites: Homewood, Alabama; Huntsville, Alabama; Mobile, Alabama · 125 sites in all
- A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00912964 · 2,030 participants · Start Apr 28, 2009 · Primary completion Apr 27, 2010
Drug: Mirabegron; Placebo · For: Urinary Bladder, Overactive
Sites: Homewood, Alabama; Huntsville, Alabama; Mobile, Alabama · 151 sites in all
- A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.Pivotal-lookingCompleted
Astellas Pharma Europe Ltd.Astellas (ALPMY)
NCT01638000 · 1,887 participants · Start Jun 12, 2012 · Primary completion Apr 24, 2013
Drug: Mirabegron; Solifenacin succinate · For: Urologic Diseases; Urinary Bladder, Overactive; Urinary Bladder Diseases
Sites: Yerevan, Armenia; Baden, Austria; Graz, Austria · 217 sites in all
- A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive BladderPivotal-lookingCompleted
Astellas Pharma Europe B.V.Astellas (ALPMY)
NCT02045862 · 1,829 participants · Start Mar 17, 2014 · Primary completion Sep 8, 2016
Drug: Solifenacin succinate; Mirabegron and 2 more · For: Urinary Bladder Overactive; Overactive Bladder; Urgency Incontinence and 1 more
Sites: Mobile, Alabama; Chandler, Arizona; Phoenix, Arizona · 251 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective5,971
- off label use2,852
- fatigue2,372
- headache2,301
- dizziness2,293
- fall2,069
- diarrhoea2,057
- pain1,921
- nausea1,831
- asthenia1,638
- hypertension1,593
- intentional product misuse1,549
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 64 |
| 2013 | 1,374 |
| 2014 | 1,949 |
| 2015 | 2,022 |
| 2016 | 2,731 |
| 2017 | 3,683 |
| 2018 | 3,916 |
| 2019 | 3,313 |
| 2020 | 3,039 |
| 2021 | 2,867 |
| 2022 | 2,797 |
| 2023 | 2,843 |
| 2024 | 3,150 |
| 2025 | 3,300 |
| 2026 | 2,119 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of overactive neurogenic bladder treatment: A systematic review of randomized controlled trials.
Bapir R, Bhatti KH, Eliwa A, et al. · Arch Ital Urol Androl 2022 · Meta-Analysis, Systematic Review
- Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis.
He W, Zhang Y, Huang G, et al. · Low Urin Tract Symptoms 2023 · Systematic Review, Network Meta-Analysis
- Posterior Tibial Nerve Stimulation With versus Without Mirabegron: A Randomized Controlled Trial.
Stanley RF, Meyer I, Blanchard CT, et al. · Int Urogynecol J 2024 · Randomized Controlled Trial, Comparative Study
- Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
He W, Huang G, Cui W, et al. · Int Braz J Urol 2023 · Systematic Review, Network Meta-Analysis
- Mirabegron as effective as oxybutynin for ureteral stent symptoms.
Jaworski P, Mello GF, Ferreira GM, et al. · Rev Assoc Med Bras (1992) 2021 · Randomized Controlled Trial
- Efficacy of mirabegron for ureteral stones: a systematic review with meta-analysis of randomized controlled trials.
Wang Z, Chi J, Liu Y, et al. · Front Pharmacol 2023 · Systematic Review
Sponsor: Apgdi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.